Publications 2021

Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U, Culine S, de Wit R, Hansen AR, Bebek M, Terbuch A, Albany C, Hentrich M, Gietema JA, Negaard H, Huddart RA, Lorch A, Cafferty FH, Heng DYC, Sweeney CJ, Winquist E et al. (2021)
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium
J Clin Oncol, 39 (14), 1553-1562
DOI 10.1200/JCO.20.03292, PubMed 33729863

Gerdtsson A, Thor A, Grenabo Bergdahl A, Almås B, Håkansson U, Törnblom M, Negaard HFS, Glimelius I, Halvorsen D, Karlsdóttir Á, Sagstuen Haugnes H, Engen Andreassen K, Melsen Larsen S, Holmberg G, Wahlqvist R, Tandstad T, Cohn-Cedermark G, Ståhl O, Kjellman A (2021)
Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group
Eur Urol Oncol (in press)
DOI 10.1016/j.euo.2021.02.002, PubMed 33750683

Gillessen S, Sauvé N, Collette L, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema JA, De Giorgi U, Cafferty FH, Hansen AR, Tandstad T, Huddart RA, Necchi A, Sweeney CJ, Garcia-Del-Muro X, Heng DYC, Lorch A, Chovanec M, Winquist E, Grimison P, Feldman DR, Terbuch A et al. (2021)
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium
J Clin Oncol, 39 (14), 1563-1574
DOI 10.1200/JCO.20.03296, PubMed 33822655

Haugnes HS, Negaard HF, Jensvoll H, Wilsgaard T, Tandstad T, Solberg A (2021)
Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study
Eur Urol Open Sci, 32, 19-27
DOI 10.1016/j.euros.2021.07.007, PubMed 34667955

Hellesnes R, Myklebust TÅ, Fosså SD, Bremnes RM, Karlsdottir Á, Kvammen Ø, Tandstad T, Wilsgaard T, Negaard HFS, Haugnes HS (2021)
Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort
J Clin Oncol, JCO2100637 (in press)
DOI 10.1200/JCO.21.00637, PubMed 34388002

Publications 2020

Hellesnes R, Myklebust TÅ, Bremnes RM, Karlsdottir Á, Kvammen Ø, Negaard HFS, Tandstad T, Wilsgaard T, Fosså SD, Haugnes HS (2020)
Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study
J Clin Oncol, 39 (4), 308-318
DOI 10.1200/JCO.20.02713, PubMed 33356420

Thorsen L, Haugnes HS, Fosså SD, Brydøy M, Tandstad T, Wisløff T, Gjerset GM, Edvardsen E, Larsen KO, Sandset PM, Henriksson CE, Raastad T, Negaard HFS (2020)
Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer: Case reports and review of the literature
Int J Cancer, 147 (11), 3189-3198
DOI 10.1002/ijc.33151, PubMed 32525564

Publications 2019

Gerdtsson A, Håkansson U, Törnblom M, Jancke G, Negaard HFS, Glimelius I, Halvorsen D, Karlsdóttir Á, Haugnes HS, Andreassen KE, Larsen SM, Holmberg G, Wahlqvist R, Tandstad T, Cohn-Cedermark G, Ståhl O, Kjellman A (2019)
Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group
Eur Urol Oncol, 3 (3), 382-389
DOI 10.1016/j.euo.2019.08.002, PubMed 31506250

Hellesnes R, Kvammen Ø, Myklebust TÅ, Bremnes RM, Karlsdottir Á, Negaard HFS, Tandstad T, Wilsgaard T, Fosså SD, Haugnes HS (2019)
Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era
Int J Cancer, 147 (1), 21-32
DOI 10.1002/ijc.32704, PubMed 31597192

Publications 2013

Iversen PO, Negaard H, Østenstad B, Sandset PM, Kolset SO (2013)
Evidence for long-term hypercoagulopathy, but normalization of markers of extracellular matrix turnover, in patients with non-Hodgkin lymphoma
Leuk Lymphoma, 56 (8), 2479-81
DOI 10.3109/10428194.2013.803227, PubMed 23656198

Publications 2011

Negaard HF, Sandset PM, Kolset SO, Svennevig K, Østenstad B, Iversen PO (2011)
Associations between regulators of extracellular matrix and hemostatic factors in hematologic neoplasias
Leuk Lymphoma, 52 (6), 1157-9
DOI 10.3109/10428194.2011.563886, PubMed 21463121

Publications 2009

Negaard HF, Svennevig K, Kolset SO, Iversen N, Lothe IM, Østenstad B, Sandset PM, Iversen PO (2009)
Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas
Leuk Lymphoma, 50 (6), 998-1004
DOI 10.1080/10428190902889270, PubMed 19373600

Publications 2008

Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B, Iversen PO (2008)
Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
Leukemia, 23 (1), 162-9
DOI 10.1038/leu.2008.255, PubMed 18800145

Negaard HF, Iversen PO, Østenstad B, Iversen N, Holme PA, Sandset PM (2008)
Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor
Thromb Haemost, 99 (6), 1040-8
DOI 10.1160/TH07-09-0541, PubMed 18521506

Negaard HF, Iversen PO, Ostenstad B, Mowinckel MC, Sandset PM (2008)
Increased acquired activated protein C resistance in unselected patients with hematological malignancies
J Thromb Haemost, 6 (9), 1482-7
DOI 10.1111/j.1538-7836.2008.03060.x, PubMed 18573186

Publications 2006

Negaard HF, Eilertsen AL, Dahm A, Iversen PO, Østenstad B, Sandset PM (2006)
Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?
J Clin Oncol, 24 (17), 2683-4; author reply 2684
DOI 10.1200/JCO.2006.06.4345, PubMed 16763285